Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 25, 2004
Business Overview: Henry Schein is the largest distributor of healthcare products and services to office-based practitioners in North America and Europe. The company operates through two segments: Healthcare Distribution (dental, medical, veterinary, and international) and Technology (practice management software and value-added services). It serves over 475,000 customers globally.
Key Financial Metrics
| Metric | 2004 (in thousands) | 2003 (in thousands) |
|---|---|---|
| Net Sales | $4,060,266 | $3,353,805 |
| Gross Profit | $1,076,406 | $927,194 |
| Gross Margin | 26.5% | 27.6% |
| Operating Income | $213,087 | $233,719 |
| Net Income | $128,183 | $137,510 |
| Diluted EPS | $1.43 | $1.53 |
| Operating Cash Flow | $190,999 | $128,843 |
| Total Debt | $535,557 | $256,412 |
| Working Capital | $736,844 | $637,296 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 21.1% to $4.06 billion, driven by a 61.0% surge in International sales (primarily due to the Demedis Group acquisition) and 17.4% growth in Dental sales.
- Profitability Decline: Despite revenue growth, Net Income decreased 6.8% to $128.2 million. This was primarily due to a one-time pre-tax charge of $13.2 million related to the Chiron Fluvirin influenza vaccine contract.
- Margin Compression: Gross margin decreased to 26.5% from 27.6%, largely attributed to the absence of high-margin Fluvirin vaccine sales in 2004.
- Debt Increase: Total debt more than doubled to $535.6 million, reflecting the issuance of $240 million in convertible debt to finance the Demedis acquisition and repay bridge loans.
- Acquisitions: The acquisition of the Demedis Group (excluding Austrian operations) significantly expanded the company's European footprint, doubling international net sales.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Item (Fluvirin Charge): The company recorded a $13.2 million charge in Q4 2004 to write off deferred expenses associated with the 2005/2006 influenza season due to uncertainty regarding Chiron's ability to supply the vaccine following a manufacturing suspension in the UK.
- Strategic Response: Henry Schein entered a multi-year agreement with ID Biomedical Corporation to distribute Fluviral influenza vaccine, pending FDA approval, to mitigate supply risks.
- Outlook: Management expects continued growth driven by an aging population, increased healthcare awareness, and industry consolidation. The company plans to invest approximately $50 million in fiscal 2005 capital projects.
- Risks:
- Supply Chain: Dependence on third-party manufacturers (e.g., Chiron) creates vulnerability to supply interruptions.
- Regulatory: Subject to extensive government regulation regarding pharmaceuticals and medical devices.
- Integration: Risks associated with integrating the Demedis Group and achieving expected synergies.
- Interest Rates: Exposure to variable interest rates on $230 million of senior notes following interest rate swaps.
Investor Verification Checklist
- Fluvirin Resolution: Verify the status of Chiron's manufacturing license and the timeline for FDA approval of the ID Biomedical Fluviral vaccine to assess future revenue stability in the vaccine segment.
- Demedis Integration: Monitor the integration progress of the Demedis Group and the regulatory outcome regarding the pending acquisition of the Austrodent business in Austria.
- Debt Servicing: Review the impact of the increased debt load ($535.6 million) on interest coverage ratios and future cash flow availability.
- Margin Recovery: Track gross margin trends in 2005 to determine if the absence of Fluvirin sales was a temporary anomaly or indicative of a structural shift in product mix.
- Stock Repurchases: Confirm the remaining capacity under the $100 million stock repurchase program authorized in June 2004.